The Manufacturers Life Insurance Company decreased its position in Sanofi (NYSE:SNY) by 5.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 576,235 shares of the company’s stock after selling 32,042 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Sanofi were worth $28,910,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of SNY. FMR LLC grew its holdings in shares of Sanofi by 19.3% in the 2nd quarter. FMR LLC now owns 21,450,971 shares of the company’s stock worth $1,095,072,000 after purchasing an additional 3,464,099 shares during the last quarter. Fisher Asset Management LLC lifted its position in Sanofi by 2.8% during the 2nd quarter. Fisher Asset Management LLC now owns 18,155,655 shares of the company’s stock worth $926,846,000 after buying an additional 493,628 shares in the last quarter. Clark Capital Management Group Inc. acquired a new position in Sanofi during the 2nd quarter worth about $24,614,000. Morgan Stanley lifted its position in Sanofi by 9.8% during the 1st quarter. Morgan Stanley now owns 5,142,760 shares of the company’s stock worth $224,842,000 after buying an additional 460,930 shares in the last quarter. Finally, GWM Advisors LLC lifted its position in Sanofi by 2,339.6% during the 2nd quarter. GWM Advisors LLC now owns 345,294 shares of the company’s stock worth $17,627,000 after buying an additional 331,140 shares in the last quarter. 7.04% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages recently issued reports on SNY. Stifel Nicolaus downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. SVB Leerink downgraded shares of Sanofi to a “market perform” rating in a research report on Tuesday, August 18th. Berenberg Bank assumed coverage on shares of Sanofi in a research report on Tuesday, September 29th. They set a “hold” rating on the stock. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Sunday, October 4th. They issued a “buy” rating on the stock. Finally, Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $53.00 target price for the company in a research note on Monday, October 19th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $55.67.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Thursday, October 29th. The company reported $1.07 EPS for the quarter, missing the Zacks’ consensus estimate of $1.09 by ($0.02). The company had revenue of $9.48 billion during the quarter, compared to analyst estimates of $9.65 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. Sanofi’s revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.92 earnings per share. As a group, analysts expect that Sanofi will post 3.1 earnings per share for the current year.
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.
Featured Article: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.